CN112771063B - 氟化胆汁酸衍生物 - Google Patents

氟化胆汁酸衍生物 Download PDF

Info

Publication number
CN112771063B
CN112771063B CN201980050077.0A CN201980050077A CN112771063B CN 112771063 B CN112771063 B CN 112771063B CN 201980050077 A CN201980050077 A CN 201980050077A CN 112771063 B CN112771063 B CN 112771063B
Authority
CN
China
Prior art keywords
compound
ethyl
cholan
formula
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980050077.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN112771063A (zh
Inventor
A·C·韦茅斯-威尔逊
G·帕克
B·J·P·林克劳
D·基德-辛克莱
K·A·沃森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nzp Uk Ltd
Original Assignee
University of Southampton
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton, Nzp Uk Ltd filed Critical University of Southampton
Publication of CN112771063A publication Critical patent/CN112771063A/zh
Application granted granted Critical
Publication of CN112771063B publication Critical patent/CN112771063B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN201980050077.0A 2018-07-30 2019-07-30 氟化胆汁酸衍生物 Active CN112771063B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1812382.8 2018-07-30
GBGB1812382.8A GB201812382D0 (en) 2018-07-30 2018-07-30 Compounds
PCT/GB2019/052127 WO2020025942A1 (en) 2018-07-30 2019-07-30 Fluorinated bile acid derivatives

Publications (2)

Publication Number Publication Date
CN112771063A CN112771063A (zh) 2021-05-07
CN112771063B true CN112771063B (zh) 2023-10-27

Family

ID=63518053

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050077.0A Active CN112771063B (zh) 2018-07-30 2019-07-30 氟化胆汁酸衍生物

Country Status (7)

Country Link
US (1) US11517577B2 (https=)
EP (1) EP3830103B8 (https=)
JP (2) JP7805783B2 (https=)
CN (1) CN112771063B (https=)
ES (1) ES2968881T3 (https=)
GB (1) GB201812382D0 (https=)
WO (1) WO2020025942A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820887D0 (en) * 2018-12-20 2019-02-06 Nzp Uk Ltd Compounds
TW202333741A (zh) * 2021-11-15 2023-09-01 大陸商海湃泰克（北京）生物醫藥科技有限公司 多環化合物及其方法
CN115819491A (zh) * 2022-12-22 2023-03-21 江苏佳尔科药业集团股份有限公司 7-酮基石胆酸及熊去氧胆酸的合成方法
WO2025020190A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025021195A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
CN119371475B (zh) * 2023-07-27 2025-11-04 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073767A1 (en) * 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
WO2016173493A1 (en) * 2015-04-28 2016-11-03 Shanghai De Novo Pharmatech Co. Ltd. Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
CN106518946A (zh) * 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用
EP3290429A1 (en) * 2015-04-28 2018-03-07 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Cholic acid derivative, and preparation method and medical use thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175320A (en) 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
ES2306459T3 (es) 1996-05-23 2008-11-01 Novartis Ag Prevencion y tratamiento de adenoma colonico o microadenoma colonico mediante acido 6-fluoroursodesoxicolico (6-fudca).
ES2248581T3 (es) 2001-03-12 2006-03-16 Intercept Pharmaceuticals, Inc. Esteroides como agonistas de fxr.
CA2466033A1 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PL1734970T3 (pl) 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
US7932244B2 (en) 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
KR101555716B1 (ko) 2007-01-19 2015-09-25 인터셉트 파마슈티컬즈, 인크. Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
WO2010014836A2 (en) 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
ES2774368T3 (es) 2008-11-19 2020-07-20 Intercept Pharmaceuticals Inc Moduladores de TGR5 y métodos de uso de los mismos
DK2698375T3 (en) 2008-11-19 2018-05-28 Intercept Pharmaceuticals Inc TGR5 modulators and methods for using them
SI3336097T1 (sl) 2012-06-19 2021-07-30 Intercept Pharmaceuticals, Inc. Priprava nekristalinične oblike obetiholne kisline
SG11201503247UA (en) 2012-10-26 2015-06-29 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
CN105164161A (zh) 2013-03-13 2015-12-16 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
TN2015000497A1 (en) 2013-05-14 2017-04-06 Intercept Pharmaceuticals Inc 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
CN104938001B (zh) 2013-12-10 2019-04-12 华为终端有限公司 一种注册方法和相关节点以及注册系统
KR102546748B1 (ko) 2014-11-19 2023-06-22 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
KR102527821B1 (ko) 2014-11-19 2023-05-02 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
EA033445B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EP3223823A4 (en) 2014-11-26 2018-10-17 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
CN105348365A (zh) 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
TW201628625A (zh) 2015-02-06 2016-08-16 英特賽普醫藥品公司 組合療法醫藥組成物
EP3256134A4 (en) 2015-02-11 2018-10-03 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN107530361A (zh) 2015-03-09 2018-01-02 英特塞普特医药品公司 用于调节骨密度的方法
WO2016145216A1 (en) 2015-03-10 2016-09-15 Metselex, Inc. Fluorinated and alkylated bile acids
US20160279393A1 (en) 2015-03-25 2016-09-29 Covidien Lp Guidewire retrieval catheter
WO2016161003A1 (en) 2015-03-31 2016-10-06 Enanta Phamraceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
TW201704251A (zh) 2015-04-29 2017-02-01 正大天晴藥業集團股份有限公司 鵝去氧膽酸衍生物
CN106210599B (zh) 2015-04-30 2021-02-12 中兴通讯股份有限公司 一种多画面调整方法、装置及多点控制单元
JP6861703B2 (ja) 2015-06-19 2021-04-21 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５修飾物質およびその使用方法
KR20180030204A (ko) 2015-07-30 2018-03-21 인터셉트 파마슈티컬즈, 인크. 담즙산 및 이의 유도체를 제조하는 방법
US10604544B2 (en) 2015-08-07 2020-03-31 Intercept Pharmaceuticals, Inc. Methods for preparation of bile acids and derivatives thereof
CA2998876A1 (en) 2015-09-21 2017-03-30 Intercept Pharmaceuticals, Inc. Methods of promoting hepatic regeneration
AU2016325619A1 (en) 2015-09-24 2018-04-12 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
MA42339A1 (fr) 2015-10-07 2019-01-31 Intercept Pharmaceuticals Inc Modulateurs du récepteur farnésoïde x
AU2016350690C1 (en) 2015-11-06 2020-04-23 Intercept Pharmaceuticals, Inc. Methods for the preparation of obeticholic acid and derivatives thereof
JP2018538331A (ja) 2015-12-22 2018-12-27 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸の多型結晶形態
CN105646634A (zh) 2016-01-29 2016-06-08 中国药科大学 奥贝胆酸杂质的制备方法
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
ES2874682T3 (es) 2016-03-11 2021-11-05 Intercept Pharmaceuticals Inc Derivados de 3-desoxi y composiciones farmacéuticas de los mismos
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608779D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073767A1 (en) * 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
WO2016173493A1 (en) * 2015-04-28 2016-11-03 Shanghai De Novo Pharmatech Co. Ltd. Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
EP3290429A1 (en) * 2015-04-28 2018-03-07 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Cholic acid derivative, and preparation method and medical use thereof
CN106518946A (zh) * 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
ES2968881T3 (es) 2024-05-14
EP3830103C0 (en) 2023-11-08
EP3830103B8 (en) 2023-12-20
WO2020025942A1 (en) 2020-02-06
EP3830103A1 (en) 2021-06-09
US11517577B2 (en) 2022-12-06
CN112771063A (zh) 2021-05-07
GB201812382D0 (en) 2018-09-12
JP2021533206A (ja) 2021-12-02
US20210299148A1 (en) 2021-09-30
JP2024088648A (ja) 2024-07-02
JP7805783B2 (ja) 2026-01-26
EP3830103B1 (en) 2023-11-08

Similar Documents

Publication Publication Date Title
CN112771063B (zh) 氟化胆汁酸衍生物
CN106661079B (zh) 用于治疗和/或预防fxr和tgr5/gpbar1介导的疾病的胆烷衍生物
JP6152149B2 (ja) 筋萎縮を阻害するための方法
CN108602811B (zh) Fxr受体激动剂
EP2019825B1 (en) Inhibitors of human immunodeficiency virus replication
JP2007509035A (ja) Ｅｇｒ−１エンハンサー要素に関連する疾患の処置
BR112018068278B1 (pt) Derivado de 3-desóxi, ácido livre, sal e conjugado de aminoácido, composição farmaceutica compreendendo o referido composto e seu uso
WO2014184271A1 (en) 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
CN115477681A (zh) 一种五环三萜皂苷衍生物及制备方法与应用
WO1996000236A1 (en) Triterpene derivative and medicinal composition
CN116514892B (zh) 甾类化合物、其制备方法和应用
HK40055914A (en) Fluorinated bile acid derivatives
HK40055914B (en) Fluorinated bile acid derivatives
CN108484510A (zh) 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用
CH641475A5 (fr) Derives acetyleniques de l'androst-4-ene, leur procede de preparation et medicament les renfermant.
FR2658516A1 (fr) Nouveaux produits sterouides comportant un radical spiro en position 17, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
EP3658566A2 (en) Side-chain modified ergosterol and stigmasterol derivatives as liver x receptor modulators
CA1072540A (fr) Procede de preparation de nouveaux 2,2-dimethyl steroides
EP0059146B1 (fr) Nouveaux médicaments dérivés de la 3-hydroxy dodécahydro benz (e) inden-7-one, produits dérivés de la 3-hydroxy dodécahydro benz (e) inden-7-one et leur procédé de préparation
JPH0873491A (ja) トリアムシノロン誘導体
CN120574193A (zh) 一种石竹烷衍生物及其制备方法和应用
EP0003090A2 (fr) Nouveaux dérivés stéroides 17 alpha-aryle ou 17 alpha-hétéroaryle, leur procédé de préparation et leur application comme médicaments et les compositions pharmaceutiques les renfermant
KR100324631B1 (ko) 에스트로겐유도체및그의염을함유하는모발생장촉진조성물
FI63422B (fi) Analogifoerfarande foer framstaellande av nya 21-salicylsyraestrar och 21-acetylsalicylsyraestrar av steroider ur pregnanserien
CN120789033A (zh) 具有抗流感病毒、抗炎活性的苯甲醇衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20250409

Address after: British Bristow

Patentee after: NZP UK Ltd.

Country or region after: Britain

Address before: British Bristow

Patentee before: NZP UK Ltd.

Country or region before: Britain

Patentee before: University OF SOUTHAMPTON

TR01 Transfer of patent right